Description
ITGB1BP3 Antibody | 61-506 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human
Homology: Predicted species reactivity based on immunogen sequence: Mouse
Immunogen: This ITGB1BP3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 27-55 amino acids from the N-terminal region of human ITGB1BP3.
Research Area: Signal Transduction
Tested Application: WB, IHC-P
Application: For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:10~50
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 26 kDa
Validation: N/A
Isoform: N/A
Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Clonality: Polyclonal
Clone: N/A
Isotype: Rabbit Ig
Conjugate: Unconjugated
Physical State: Liquid
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: batch dependent
Storage Condition: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Alternate Name: Nicotinamide riboside kinase 2, NRK 2, NmR-K 2, Integrin beta-1-binding protein 3, Muscle integrin-binding protein, MIBP, Nicotinic acid riboside kinase 2, Ribosylnicotinamide kinase 2, RNK 2, Ribosylnicotinic acid kinase 2, NMRK2, ITGB1BP3, NRK2
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: ITGB1BP3 catalyzes the phosphorylation of nicotinamide riboside (NR) and nicotinic acid riboside (NaR) to form nicotinamide mononucleotide (NMN) and nicotinic acid mononucleotide (NaMN) . The protein reduces laminin matrix deposition and cell adhesion to laminin, but not to fibronectin. It is involved in the regulation of PXN at the protein level and of PXN tyrosine phosphorylation and may play a role in the regulation of terminal myogenesis.